Semaglutide
In stockNN953531-residue analogue of glucagon-like peptide-1 carrying a C18 fatty diacid chain, a GLP-1 receptor agonist. Researchers study its receptor pharmacology and long-acting peptide design.
Supplied as a single-chamber lyophilized vial with a colour-coded cap (Weight Regulation).
Research literature, not dosing or treatment instructions.
- A historical review charts efforts to extend the half-life of GLP-1 and the development of long-acting GLP-1 receptor agonists, including semaglutide. (PMID 31031702)
- The GLP-1 receptor has been resolved structurally by X-ray crystallography and cryo-electron microscopy; see the incretin receptor page. (PMID 28562585, PMID 29466332)
Add the solvent slowly along the vial wall; swirl gently, never shake. Allow to dissolve fully. Six-step guide with photos →
Concentration calculator only. Enter the mass being calculated; blend components are not added automatically. Products are for in-vitro research.
Refer to the product label and supplier documentation for storage conditions. Lot-specific storage and expiry information is not available here.
Each certificate is published with its lot number.
Questions about Semaglutide
How much published research is there on Semaglutide?
The research library's PubMed search for Semaglutide returned 210 records on 5 October 2026, 40 of them reviews. The library lists 4 studies chosen for what they measured. ClinicalTrials.gov lists 778 registered studies naming Semaglutide (checked 5 October 2026).
Is Semaglutide an approved medicine?
Medicinal products containing Semaglutide appear in Drugs@FDA, and the research material we supply is not one of them. Drugs@FDA lists 6 applications naming this active ingredient, marketing status as listed: Prescription, Discontinued, None (Tentative Approval) (checked 5 October 2026). Those are medicinal products. The research material we supply is not one of them. Medicinal products containing semaglutide are authorised by the US FDA, the European Commission and the MHRA. The EMA and the Heads of Medicines Agencies warned on 3 September 2025 about illegal medicines marketed as GLP-1 receptor agonists, naming semaglutide, liraglutide and tirzepatide. It is supplied for in-vitro laboratory research only, not for human or veterinary use.
Is the research material the same as the authorised medicine?
No. Medicinal products containing semaglutide are authorised by regulators, and the research material supplied here is not one of them. It is supplied for in-vitro research only.
Why does the literature list show no clinical papers?
Clinical papers on semaglutide state clinical outcomes in their titles and endpoints, so the research library lists only chemistry, pharmacology and analytical papers.
How does Semaglutide differ from Tirzepatide?
Semaglutide is a lipidated GLP-1 analogue acting at the GLP-1 receptor. Tirzepatide is a larger lipidated peptide acting at both the GIP and GLP-1 receptors. The comparison covers chemistry, receptor targets and regulatory position only.
How is the identity of Semaglutide confirmed on a certificate?
A research-grade certificate of analysis typically reports identity by mass spectrometry and purity by HPLC. The mass result is read against the average molecular weight of 4113.6 Da listed on this page. The research library's guide to reading a certificate explains each field.
Is this product for human use?
No. Peptency products are supplied for in-vitro research only. Not for human or veterinary use, not for diagnosis or therapy.
Where can I find shipping information?
Current shipping rates and delivery information are on the Shipping & payment page, and the rates that apply to your order are shown at checkout.
Often studied with
For research use only. Not for human or veterinary use.
What is Semaglutide?
Semaglutide is a 31-residue analogue of glucagon-like peptide-1 (GLP-1) carrying a C18 fatty diacid chain. It acts as a GLP-1 receptor agonist. The research material is not the authorised medicine. We supply Semaglutide as a lyophilized vial for in-vitro laboratory research only.
What are the chemical identifiers of Semaglutide?
Semaglutide has the molecular formula C187H291N45O59, an average molecular weight of 4113.6 Da and CAS number 910463-68-2.
Chemistry checked against PubChem (CID 56843331), 5 October 2026; full chemistry record in the research library.
What does published research on Semaglutide cover?
A PubMed search for Semaglutide returned 210 records on 5 October 2026, 40 of them reviews. Our research library lists 4 of these studies, chosen for what they measured.
- A historical review charts efforts to extend the half-life of GLP-1 and the development of long-acting GLP-1 receptor agonists, including semaglutide. (Knudsen et al., Front Endocrinol (Lausanne), 2019; PMID 31031702)
- The GLP-1 receptor has been resolved structurally by X-ray crystallography and cryo-electron microscopy; see the incretin receptor page. (Jazayeri et al., Nature, 2017; PMID 28562585; Liang et al., Nature, 2018; PMID 29466332)
Mechanism, every cited study and the regulator records are on the Semaglutide page of the research library. Papers are listed by what they measured, not as evidence of any use.
How is Semaglutide supplied and stored?
Semaglutide is supplied as a lyophilized (freeze-dried) powder in a sealed vial, for in-vitro laboratory research only. Our stated storage condition for the sealed lyophilized vial is 2 to 8 °C. The label and the lot certificate carry the lot-specific storage condition and expiry date.
What is the regulatory status of Semaglutide?
Drugs@FDA lists 6 applications naming this active ingredient, marketing status as listed: Prescription, Discontinued, None (Tentative Approval) (checked 5 October 2026). Those are medicinal products. The research material we supply is not one of them.
Medicinal products containing semaglutide are authorised by the US FDA, the European Commission and the MHRA. The EMA and the Heads of Medicines Agencies warned on 3 September 2025 about illegal medicines marketed as GLP-1 receptor agonists, naming semaglutide, liraglutide and tirzepatide.
A regulator record is information about a database entry. It is not advice and not a statement that any use is lawful or unlawful in any country. How regulators approach research peptides.
Which related research pages and compounds are listed?
- Semaglutide: chemistry, literature and regulatory status
- Semaglutide compared with Tirzepatide
- Incretin and glucagon receptors
- How to read a certificate of analysis
Related compounds in the catalog: